CEL-SCINYSE American: CVM

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

CEL-SCI is in the Healthcare sector

CEL-SCI is in the Biotechnology industry

CEL-SCI is headquartered in United States

CEL-SCI initial public offering (IPO) was on 08 December 1983

https://cel-sci.com

No, CEL-SCI is not included in the S&P 500 index

No, CEL-SCI is not included in the NASDAQ 100 index

No, CEL-SCI is not included in the Dow Jones index

No data